drugset / Trial / NCT00574912
Characteristics of Glargine in Type 2 Diabetics
NaSingle-groupOpen-labelTreatment
Summary
The study is to determine the dose response relationship of insulin glargine in type 2 diabetes over a 24-hour period and measuring the differences in glucose production among the differing doses of glargine. Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes will show differing effects on endogenous glucose production, glucose disposal and carbohydrate and lipid flux.
Timeline
- Start
- 2007-03
- Primary completion
- 2009-09
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin glargine | Protein / enzyme biologic | 0.5 iu/kg | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | 1 iu/kg | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | 1.5 iu/kg | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | 2 iu/kg | Subcutaneous |